Oslo, Norway, 9 February 2024 Vistin Pharma ASA will release its fourth quarter and preliminary 2023 results on Friday 16th of February 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Friday 16th of February at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The fourth quarter conference call will be available via web and audio through the following access points: Webcast: https://edge.media-server.com/mmc/p/zfievj3m Telephone conference (online registration): https://register.vevent.com/register/BI4f66989ce55146f7ba76754c37cdec44 ***** For further information, please contact: Alexander KarlsenCFO+47 97053621alexander.karlsen@vistin.com About Vistin Pharma | www.vistin.com Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.